CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
Takashi Seto, Katsuyuki Kiura, Makoto Nishio et al. · The Lancet Oncology · 2013
Cited by 575 works. doi:10.1016/s1470-2045(13)70142-6
Authors
- Takashi Seto
- Katsuyuki Kiura
- Makoto Nishio
- Kazuhiko Nakagawa
- Makoto Maemondo
- Akira Inoue
- Toyoaki Hida
- Nobuyuki Yamamoto
- Hiroshige Yoshioka
- Masao Harada
- Yuichiro Ohe
- Naoyuki Nogami
- Kengo Takeuchi
- Tadashi Shimada
- Tomohiro Tanaka
- Tomohide Tamura
References
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- RET, ROS1 and ALK fusions in lung cancer
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer